Register Login

KalVista Pharmaceuticals Inc (KALV)

(90% Positive) KALVISTA PHARMACEUTICALS, INC. (KALV) Announces Enrollment Update for interest Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 9:49 p.m.

    📋 KALVISTA PHARMACEUTICALS, INC. (KALV) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 16:47:09

    Event Type: Clinical Trial Update

    Event Details:

    KalVista Pharmaceuticals Inc (KALV) Announces Clinical Trial Update KalVista Pharmaceuticals Inc (KALV) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: interest, treatment
    • Diseases/Conditions: Latin America, Germany
    • Collaboration: KalVista Pharmaceuticals Provides Update
    • Updated Timeline: the fourth quarter and full year 2025, fourth quarter and full year ended December 31, 2025
      • anticipated in 2027
      • planned for 2026
      • anticipated in key global markets, EKTERLY has the potential to become the foundational therapy for HAE management worldwide. For more information, including the full US Prescribing Information, visit EKTERLY.com. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (KALVISTA PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Sebetralstat DRUG Preclinical Hereditary Angioedema ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KalVista Pharmaceuticals Inc
    • CIK: 0001348911
    • Ticker Symbol: KALV
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories